CORRECTION: Mirum Pharmaceuticals Q2 Adj. EPS $(0.80) Misses $(0.68) Estimate, Sales $176.243M Beat $166.122M Estimate
Mirum Pharmaceuticals (NASDAQ:MIRM) reported quarterly losses of $(0.80) per share which missed the analyst consensus estimate of $(0.68) by 17.65 percent. This is a 566.67 percent decrease over losses of $(0.12) per
Mirum lost more money per share than experts thought it would, which is disappointing. But the company sold more products than expected, which shows customers still want what they make.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.